Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance
Ruben J. Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 5, pp. 524-539
Open Access | Times Cited: 16

Showing 16 citing articles:

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
Ronen Stein, Dan Turner, Séamus Hussey, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 1
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review
Chen Wang, Yu Gu, Qiao Chu, et al.
Microbiological Research (2024) Vol. 282, pp. 127660-127660
Closed Access | Times Cited: 8
Long-term VEDOKIDS results: implications for practice and research
Elizabeth Spencer
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab
Courtney A. Bartel, Phillip Minar
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
Gut Microbiota in Different Treatment Response Types of Crohn’s Disease Patients Treated with Biologics over a Long Disease Course
Xiaolei Zhao, Jun Xu, Dong Wu, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 708-708
Open Access
Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review
Susanna Meade, Jeremy Liu Chen Kiow, Cristian Aldo Massaro, et al.
Gut Microbes (2023) Vol. 15, Iss. 2
Open Access | Times Cited: 13
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
Tina Deyhim, Adam S. Cheifetz, Konstantinos Papamichael
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 7132-7132
Open Access | Times Cited: 12
Challenges in IBD Research 2024: Pragmatic Clinical Research
Jessica R. Allegretti, Liliana Bordeianou, Oriana M. Damas, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S55-S66
Open Access | Times Cited: 1
Current Role of Monoclonal Antibody Therapy in Pediatric IBD: A Special Focus on Therapeutic Drug Monitoring and Treat-to-Target Strategies
M. Classen, André Hoerning
Children (2023) Vol. 10, Iss. 4, pp. 634-634
Open Access | Times Cited: 3
The Role of Therapeutic Drug Monitoring in Children
Alexander Nasr, Phillip Minar
Gastroenterology Clinics of North America (2023) Vol. 52, Iss. 3, pp. 549-563
Open Access | Times Cited: 2
Considerations in Paediatric and Adolescent Inflammatory Bowel Disease
S Vuijk, A Camman, Lissy de Ridder
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. Supplement_2, pp. ii31-ii45
Open Access
Vedolizumab Clearance as a Surrogate Marker for Remission in Inflammatory Bowel Disease Patients: Insights from Real-World Pharmacokinetics
Srđan Marković, Đorđe Kralj, Petar Svorcan, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1629-1629
Open Access
De Novo Crohn’s Disease Diagnosed in the Setting of Acute SARSCov- 2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics
Martin Varea Romo, Kishor Acharya, Nathan R. Shelman, et al.
Journal of Pediatrics Perinatology and Child Health (2024) Vol. 08, Iss. 01
Open Access
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease
S Vuijk, Lissy de Ridder
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 5, pp. 565-566
Open Access | Times Cited: 1
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease—authors' reply
Ruben J. Colman, Phillip Minar
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 5, pp. 567-568
Open Access
Page 1

Scroll to top